semaglutide lean mass loss Changes in body with glucagon‐like peptide‐1‐based therapies and mitigation strategies - Neeland - 2024 - Diabetes, Obesity and Metabolism effect of semaglutide on muscle

Iwabuchi T, Yoshimoto C, Shigetomi H, Kobayashi H

Overweight with Comorbidities For individuals with BMI 27-30 who have metabolic complications type 2 diabetes, MASLD, dyslipidemia, hypertension retatrutide's multi-system benefits address multiple conditions simultaneously rather than treating each one separately

Other strategies include providing counseling regarding the potential gastrointestinal adverse events that could arise, such as nausea, vomiting, and diarrhea

Patients with a family history of medullary thyroid carcinoma should also avoid taking semaglutide

Sulforaphane represses matrix-degrading proteases and protects cartilage from destruction in vitro and in vivo